BioMerieux SA (FRA:EYWN) Stock Price, Trades & News

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	1.24
Equity-to-Asset	0.74
Debt-to-Equity	0.11
Debt-to-EBITDA	0.54
Interest Coverage	43.97
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.9	Distress Grey Safe
Beneish M-Score	-2.88	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	4.1
	3-Year EBITDA Growth Rate	0.5
	3-Year EPS without NRI Growth Rate	4.2
	3-Year FCF Growth Rate	33.8
	3-Year Book Growth Rate	4.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	13.83
	Future 3-5Y Total Revenue Growth Rate Estimate	4.94

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	60.74
	9-Day RSI	52.32
	14-Day RSI	47.93
	3-1 Month Momentum %	-18.34
	6-1 Month Momentum %	-33.3
	12-1 Month Momentum %	-38.38

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.39
	Quick Ratio	1.48
	Cash Ratio	0.54
	Days Inventory	205.26
	Days Sales Outstanding	67.17
	Days Payable	52.74

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.41
	Dividend Payout Ratio	0.2
	3-Year Dividend Growth Rate	1.9
	Forward Dividend Yield %	1.41
	5-Year Yield-on-Cost %	4.9
	Shareholder Yield %	2.08

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	56.73
	Operating Margin %	17.07
	Net Margin %	9.77
	EBITDA Margin %	20.85
	FCF Margin %	11.13
	OCF Margin %	19.37
	ROE %	9.74
	ROA %	7.14
	ROIC %	12.07
	3-Year ROIIC %	14.15
	ROC (Joel Greenblatt) %	20.9
	ROCE %	12.03
	Years of Profitability over Past 10-Year	10
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	21.33
	Forward PE Ratio	15.3
	PE Ratio without NRI	15.83
	Shiller PE Ratio	19.39
	Price-to-Owner-Earnings	16.36
	PS Ratio	2.08
	PB Ratio	2.05
	Price-to-Tangible-Book	2.83
	Price-to-Free-Cash-Flow	18.72
	Price-to-Operating-Cash-Flow	10.76
	EV-to-EBIT	15.33
	EV-to-Forward-EBIT	12.8
	EV-to-EBITDA	9.78
	EV-to-Forward-EBITDA	8.72
	EV-to-Revenue	2.04
	EV-to-Forward-Revenue	2.1
	EV-to-FCF	18.32
	Price-to-GF-Value	0.65
	Price-to-Projected-FCF	1.31
	Price-to-Median-PS-Value	0.6
	Price-to-Graham-Number	1.41
	Price-to-Net-Current-Asset-Value	7.87
	Earnings Yield (Greenblatt) %	6.52
	FCF Yield %	5.39
	Forward Rate of Return (Yacktman) %	3.65

Financials (Next Earnings Date:2026-07-28)

Annual Quarterly TTM

FRA:EYWN's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

BioMerieux SA Executives

Details

GF Value™: €107.27

FRA:EYWN

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with EYWN. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	4,069.8
	EPS (TTM) (€)	3.34
	Beta	0.3446
	3-Year Sharpe Ratio	-0.36
	3-Year Sortino Ratio	-0.45
	Volatility %	27.68
	14-Day RSI	47.93
	14-Day ATR (€)	1.392563
	20-Day SMA (€)	69.395
	12-1 Month Momentum %	-38.38
	52-Week Range (€)	65.2 - 130.6
	Shares Outstanding (Mil)	117.95

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

BioMerieux SA Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

BioMerieux SA Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings conference call for 2026	2026-07-28	In 29 days
Second quarter earnings results for 2026	2026-07-28	In 29 days
EUR 0.980000 Cash Dividend	2026-06-09	71.70 (+0.00%)
General meeting for 2026	2026-05-28	71.60 (+0.00%)
First quarter earnings conference call for 2026	2026-04-23 14:00	90.25 (+0.00%)
First quarter earnings results for 2026	2026-04-23	90.25 (+0.00%)
Annual report for 2025	2026-03-17	94.80 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-27	95.25 (+0.00%)
Fourth quarter earnings results for 2025	2026-02-27	95.25 (+0.00%)
Second quarter earnings conference call for 2025	2025-09-04	115.70 (+0.00%)

Show

Entries

BioMerieux SA Frequently Asked Questions

What is BioMerieux SA(FRA:EYWN)'s stock price today?

The current price of FRA:EYWN is €69.45. The 52 week high of FRA:EYWN is €130.60 and 52 week low is €65.20.

When is next earnings date of BioMerieux SA(FRA:EYWN)?

The next earnings date of BioMerieux SA(FRA:EYWN) is 2026-07-28.

Does BioMerieux SA(FRA:EYWN) pay dividends? If so, how much?

The Dividend Yield % of BioMerieux SA(FRA:EYWN) is 1.41% (As of Today), Highest Dividend Payout Ratio of BioMerieux SA(FRA:EYWN) was 0.22. The lowest was 0.05. And the median was 0.15. The Forward Dividend Yield % of BioMerieux SA(FRA:EYWN) is 1.41%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	bioMérieux introduces Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry	2026-06-18
	First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries	2026-04-20
	bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing	2026-04-09
	bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality	2026-02-18
	OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence	2025-08-26
	bioMérieux Develops Game Changing Quality Control Solution GENE-UP® PRO HRM	2025-08-05
	bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance	2025-03-18
	bioMérieux Launches GENE-UP® TYPER,an Innovative Diagnostic Solution for Food Industries to Rapidly Analyze the Root Causeof Contamination of Listeria monocytogenes	2025-02-13
	Global In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia	2024-09-18
	bioMérieux Introduces GENE-UP® ENVIROPRO™	2023-02-02

10/Page

Articles on BioMerieux SA

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.